RESUMO
Progressive multifocal leukoencephalopathy (PML) has been associated with the use of a number of multiple sclerosis (MS) immunomodulatory therapies and has assumed a critical place in the evaluation of their benefit/risk. In this review, we discuss the European Union regulatory approach to drug-induced PML in MS, highlight a number of key issues related to the current knowledge on PML, and outline possible paths to help progress the risk management of patients with MS at risk of PML.
Assuntos
União Europeia , Fatores Imunológicos/efeitos adversos , Leucoencefalopatia Multifocal Progressiva/induzido quimicamente , Esclerose Múltipla/tratamento farmacológico , Anticorpos Monoclonais Humanizados/efeitos adversos , Europa (Continente)/epidemiologia , Humanos , Leucoencefalopatia Multifocal Progressiva/epidemiologia , Leucoencefalopatia Multifocal Progressiva/imunologia , Esclerose Múltipla/epidemiologia , Esclerose Múltipla/imunologia , Natalizumab/efeitos adversos , Medição de Risco/legislação & jurisprudência , Fatores de RiscoRESUMO
AC-1 and TFG-1 are both herb extracts from Avena Sativa and Trigonella Foenum Graecum respectively. In folk medicine, Trigonella Foenum Graecum is used as appetiser and general tonic as well as for pellagra treatment and for treatment of pulmonary disorders. Avena Sativa is another commonly used appetiser and tonic. In our study we examined the influence of AC-1 and TFG-1 on some of the major functions of the central nervous system. We divided the test animals in three groups and after administering the herb extracts we monitored different pharmacological parameters-Phenamine toxicity and stereotypy, Hexobarbital sleep, elementary conditioned reflexes and antiseizure activity.